Illumina, Inc. $ILMN Shares Sold by Generali Asset Management SPA SGR

Generali Asset Management SPA SGR cut its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 98.5% during the fourth quarter, HoldingsChannel.com reports. The fund owned 331 shares of the life sciences company’s stock after selling 21,918 shares during the quarter. Generali Asset Management SPA SGR’s holdings in Illumina were worth $43,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of ILMN. Board of the Pension Protection Fund acquired a new stake in Illumina during the 4th quarter worth $26,000. Creative Capital Management Investments LLC increased its stake in Illumina by 160.0% in the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 120 shares during the period. TD Waterhouse Canada Inc. purchased a new stake in shares of Illumina in the fourth quarter valued at about $26,000. Laurel Wealth Advisors LLC purchased a new stake in shares of Illumina in the fourth quarter valued at about $26,000. Finally, Quent Capital LLC acquired a new stake in shares of Illumina during the third quarter worth about $29,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently issued reports on ILMN shares. JPMorgan Chase & Co. boosted their price target on Illumina from $120.00 to $125.00 and gave the company a “neutral” rating in a research report on Friday, May 1st. UBS Group reiterated a “neutral” rating and issued a $135.00 target price on shares of Illumina in a research note on Friday, February 6th. Barclays boosted their target price on Illumina from $110.00 to $122.00 and gave the company an “underweight” rating in a report on Friday, May 1st. Evercore restated an “outperform” rating on shares of Illumina in a research note on Friday, May 1st. Finally, Robert W. Baird set a $137.00 price objective on shares of Illumina in a research report on Friday, February 6th. Six equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Illumina presently has an average rating of “Hold” and an average price target of $131.06.

Illumina Stock Performance

Shares of ILMN stock opened at $141.88 on Monday. The company has a market cap of $21.47 billion, a price-to-earnings ratio of 25.80, a price-to-earnings-growth ratio of 2.35 and a beta of 1.42. The stock has a 50 day simple moving average of $126.86 and a 200-day simple moving average of $127.86. Illumina, Inc. has a 12-month low of $75.24 and a 12-month high of $155.53. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. The firm had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, equities analysts forecast that Illumina, Inc. will post 5.2 EPS for the current year.

Insider Activity

In other Illumina news, SVP Christensen Jakob Wedel sold 700 shares of the stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total value of $97,328.00. Following the completion of the transaction, the senior vice president directly owned 15,056 shares of the company’s stock, valued at approximately $2,093,386.24. This trade represents a 4.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 2,370 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total value of $275,346.60. Following the sale, the senior vice president directly owned 16,321 shares in the company, valued at $1,896,173.78. This trade represents a 12.68% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 2.90% of the company’s stock.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.